Therapix Biosciences (NASDAQ:TRPX) reported topline results from its Phase 2a clinical study of THX-110 for the treatment of obstructive sleep apnea (OSA). THX-110 is a combination of dronabinol, or synthetic THC, and...
Kadmon Holdings’ (NYSE:KDMN) KD025 met its primary endpoint at an interim analysis of its registrational chronic graft-versus-host disease (cGVHD) trial. cGvHD is a deadly complication of hematopoietic stem cell...
The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor breakthrough therapy designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or...
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) will highlight its lead product candidate, Bria-IMT, in two poster sessions during the 2019 San Antonio Breast Cancer Symposium. The Dec. 12 poster will summarize the data...
Imagin Medical (CSE:IME; OTCQB:IMEXF) is making progress towards design verification of its i/Blue Imaging System functional product. The company has purchased and received components from established suppliers to meet...
The board of Cellular Biomedicine Group (NASDAQ:CBMG) received a preliminary non-binding proposal from a consortium led by Tony Liu, CEO of Cellular, to acquire all the shares outstanding at a price of $19.50 each in a...
Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) and its collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American...
A new study in the peer-reviewed Journal of Psychopharmacology suggests that cannabis has an uplifting effect on people with post traumatic stress disorder (PTSD) and may a therapeutic role in addressing the condition...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...
Opsens (TSX:OPS; OTCQX:OPSSF) announced the world’s first clinical use of its OptoWire III at the Quebec Heart and Lung Institute, following Health Canada’s recent approval of the device. OptoWire III is a...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...
Amplitude Ventures of Montreal has launched a $200-million venture fund, closing more than 50% of its target. Amplitude is a spinout of the Business Development Bank of Canada, which is a cornerstone investor in...
Inovio Pharmaceuticals (NASDAQ:INO) reported positive interim results from its Phase 2 study of INO-5401 for the treatment of newly-diagnosed glioblastoma multiforme (GBM), the most common and aggressive type of brain...
Upstart Notch Therapeutics plans to commercialize industrial-scale allogeneic gene-edited T cell therapies to deliver cost-effective treatments to patients with cancer or immune deficiencies. Incubated at Toronto’s...
Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) signed a binding share purchase agreement for the proposed saleof its Isle of Man-based bioseparations business operated through subsidiary Prometic Bioseparations (PBL) to...
Kane Biotech (TSXV:KNE) retained GR Consulting to develop and implement an out-licensing strategy for its DispersinB wound care hydrogel for both the U.S. and European markets. “Gary and Edwin have years of experience...
REGENXBIO (NASDAQ:RGNX) exercised its option to license Clearside Biomedical’s (NASDAQ:CLSD) in-office, SCS Microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics. The agreement includes, but...
Biostage (OTCQB:BSTG) filed an IND with the FDA for its Cellspan esophageal implant (CEI). According to Biostage, patients who require surgical treatment for esophageal disease have complication rates of more than 50%...
Surmodics (NASDAQ:SRDX) received FDA breakthrough device designation for its sirolimus-coated balloon (SCB), called Sundance, for the treatment of critical limb ischemia (CLI) and below-the-knee arterial disease. CLI...
TG Therapeutics (NASDAQ:TGTX) reported the follicular lymphoma (FL) cohort of the its Phase 2b pivotal trial of umbralisib met the primary endpoint of overall response rate (ORR). The trial included 188 FL patients who...
Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) plans to present two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension (PAH) at the American Heart Association annual...